Nyxoah S.A. (NYXH)
USD 5.98
(-2.76%)
USD 5.98
(-2.76%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.69 Million EUR | -82.83% |
| 2022 | 1.93 Million EUR | 252.28% |
| 2021 | 549 Thousand EUR | 1307.69% |
| 2020 | 39 Thousand EUR | 109.01% |
| 2019 | -433 Thousand EUR | 82.84% |
| 2018 | -2.52 Million EUR | -19.57% |
| 2017 | -2.11 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 156 Thousand EUR | -58.29% |
| 2024 Q2 | -170 Thousand EUR | 214.1% |
| 2023 Q1 | 266 Thousand EUR | -68.41% |
| 2023 Q3 | 640 Thousand EUR | -6.98% |
| 2023 Q2 | 688 Thousand EUR | 158.65% |
| 2023 FY | 332 Thousand EUR | -82.83% |
| 2023 Q4 | 374 Thousand EUR | -41.56% |
| 2022 Q2 | 601 Thousand EUR | 61.99% |
| 2022 Q1 | 371 Thousand EUR | 95.26% |
| 2022 FY | 1.93 Million EUR | 252.28% |
| 2022 Q3 | 119 Thousand EUR | -80.2% |
| 2022 Q4 | 842 Thousand EUR | 607.56% |
| 2021 Q2 | 107 Thousand EUR | -19.55% |
| 2021 Q3 | 121 Thousand EUR | 13.08% |
| 2021 FY | 549 Thousand EUR | 1307.69% |
| 2021 Q4 | 190 Thousand EUR | 57.02% |
| 2021 Q1 | 133 Thousand EUR | 133.33% |
| 2020 Q3 | -115 Thousand EUR | 40.72% |
| 2020 Q1 | -120 Thousand EUR | 38.46% |
| 2020 FY | 39 Thousand EUR | 109.01% |
| 2020 Q4 | -399 Thousand EUR | -246.96% |
| 2020 Q2 | -194 Thousand EUR | -61.67% |
| 2019 Q3 | -195 Thousand EUR | -6.56% |
| 2019 Q4 | -195 Thousand EUR | 0.0% |
| 2019 Q2 | -183 Thousand EUR | 0.0% |
| 2019 FY | -433 Thousand EUR | 82.84% |
| 2019 Q1 | -183 Thousand EUR | 0.0% |
| 2018 FY | -2.52 Million EUR | -19.57% |
| 2017 FY | -2.11 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 56.3 Million USD | 95.219% |
| AngioDynamics, Inc. | 154.69 Million USD | 98.26% |
| AtriCure, Inc. | 300.37 Million USD | 99.104% |
| Avinger, Inc. | 2 Million USD | -34.398% |
| Azenta, Inc. | 263.14 Million USD | 98.977% |
| BioLife Solutions, Inc. | 46.75 Million USD | 94.242% |
| The Cooper Companies, Inc. | 2.35 Billion USD | 99.886% |
| Daxor Corporation | 1.1 Million USD | -143.964% |
| Ekso Bionics Holdings, Inc. | 9.07 Million USD | 70.349% |
| Femasys Inc. | 691.9 Thousand USD | -289.073% |
| GlucoTrack, Inc. | -13 Thousand USD | 20807.692% |
| Harvard Bioscience, Inc. | 60.86 Million USD | 95.577% |
| Hologic, Inc. | 2.22 Billion USD | 99.879% |
| ICU Medical, Inc. | 739.87 Million USD | 99.636% |
| Intuitive Surgical, Inc. | 4.72 Billion USD | 99.943% |
| KORU Medical Systems, Inc. | 16.7 Million USD | 83.888% |
| LeMaitre Vascular, Inc. | 127.04 Million USD | 97.881% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 2355.948% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 2355.948% |
| Masimo Corporation | 1 Billion USD | 99.732% |
| Microbot Medical Inc. | -106 Thousand USD | 2639.623% |
| Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | 91.866% |
| Merit Medical Systems, Inc. | 583.87 Million USD | 99.539% |
| Nephros, Inc. | 8.4 Million USD | 67.971% |
| NovoCure Limited | 381.05 Million USD | 99.294% |
| NEXGEL, Inc. | 619 Thousand USD | -334.895% |
| NEXGEL, Inc. | 619 Thousand USD | -334.895% |
| Singular Genomics Systems, Inc. | -558 Thousand USD | 582.437% |
| OraSure Technologies, Inc. | 179.42 Million USD | 98.5% |
| Pro-Dex, Inc. | 14.55 Million USD | 81.5% |
| Pulse Biosciences, Inc. | -1.2 Million USD | 323.032% |
| Predictive Oncology Inc. | 1.14 Million USD | -135.048% |
| Precision Optics Corporation, Inc. | 5.79 Million USD | 53.568% |
| QuidelOrtho Corporation | 1.49 Billion USD | 99.82% |
| Repligen Corporation | 315.22 Million USD | 99.146% |
| Sanara MedTech Inc. | 57.13 Million USD | 95.289% |
| STAAR Surgical Company | 252.65 Million USD | 98.934% |
| Sharps Technology, Inc. | -891.24 Thousand USD | 402.048% |
| Utah Medical Products, Inc. | 30.03 Million USD | 91.038% |
| DENTSPLY SIRONA Inc. | 2.08 Billion USD | 99.871% |
| Jin Medical International Ltd. | 6.78 Million USD | 60.323% |